Shanghai Haohai Biological Technology Co (HKSE:06826) Debt-to-Revenue : 0.08 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Haohai Biological Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$11 Mil. Shanghai Haohai Biological Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$220 Mil. Shanghai Haohai Biological Technology Co's annualized Revenue for the quarter that ended in Mar. 2024 was HK$2,807 Mil. Shanghai Haohai Biological Technology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.08.

Shanghai Haohai Biological Technology Co Debt-to-Revenue Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Debt-to-Revenue Chart

Shanghai Haohai Biological Technology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.03

0.08

0.06

0.16

Shanghai Haohai Biological Technology Co Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															-	0.08	0.10	0.16	0.08

Competitive Comparison of Shanghai Haohai Biological Technology Co's Debt-to-Revenue

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Haohai Biological Technology Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Debt-to-Revenue falls into.

Shanghai Haohai Biological Technology Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Haohai Biological Technology Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(236.94	+	209.266)	/	2882.009
	=	0.15

Shanghai Haohai Biological Technology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(10.863	+	220.326)	/	2806.98
	=	0.08

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Shanghai Haohai Biological Technology Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

688366:China

Address

No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN

Website

https://www.3healthcare.com

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Executives

Morgan Stanley	2201 Interest of corporation controlled by you
Dalton Investments Llc	2102 Investment manager
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Templeton Investment Counsel, Llc	2102 Investment manager
Kabouter Management Llc	2102 Investment manager
Royal Bank Of Canada	2201 Interest of corporation controlled by you
Kabouter International Insight Fund, Llc	2102 Investment manager
Prudence Investment Management (hong Kong) Limited	2102 Investment manager

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines